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Stem cell abnormalitiesDiabetic peripheral neuropathy is a major chronic diabetic complication. We have previously shown
that in type 1 diabetic streptozotocin-treated mice, insulin- and TNF-a co-expressing bone marrow-
derived cells (BMDCs) induced by hyperglycemia travel to nerve tissues where they fuse with nerve
cells, causing premature apoptosis and nerve dysfunction. Here we show that similar BMDCs also
occur in type 2 diabetic high-fat diet (HFD) mice. Furthermore, we found that hyperglycemia
induces the co-expression of insulin and TNF-a in c-kit+Sca-1+lineage (KSL) progenitor cells, which
maintain the same expression pattern in the progeny, which in turn participates in the fusion with
neurons when transferred to normoglycemic animals.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Peripheral neuropathy is one of the most common complica-
tions in diabetic patients. The pathogenesis of diabetic neuropathy
involves multiple factors such as damage to nerve cells as well as
impairments of microvascular vessels that supply nerves which
includes, oxidative stress, activation of the polyol pathway, in-
creased advanced glycation end products (AGE), activation of pro-
tein kinase C (PKC) and mitogen activated protein kinases, growth
factor deﬁciency and elevation of cytokines such as tumor necrosis
factor (TNF)-a and IL-6, and deﬁciency of nerve growth factor
(NGF) [1,2]. Diabetic neuropathy, however, does not remit
completely in response to glycemic control or treatment with
drugs such as antioxidants, prostaglandins, aldose reductase inhib-
itors, AGE inhibitors, or PKC inhibitors [3]. These facts suggest that
other additional factors may be involved in the pathogenesis of
diabetic neuropathy.Recently, many reports have implicated abnormal bone mar-
row-derived cells (BMDCs) in the onset of diabetic complications
such as retinopathy, nephropathy, and macroangiopathy [4–6].
Our laboratory also reported the presence of abnormal BMDCs
marked by ectopic insulin (mostly as proinsulin) and TNF-a co-
expression in liver and dorsal root ganglia (DRG) under diabetic
conditions [1,7,8]. In addition, surprisingly, we found that the
abnormal BMDCs were fused with DRG neurons, resulting in neu-
ronal dysfunction and diabetic neuropathy in STZ-induced type 1
diabetic mice [1]. It is unclear, however, if a similar mechanism
happens in type 2 diabetes, and further, which particular BM pop-
ulation is affected by hyperglycemia, and how it promotes the
development of diabetic complications.
In this report, we ﬁrst investigated the appearance of abnormal
BMDCs and their fusion with DRG neurons under hyperglycemic
condition in mouse models of both type 1 and type 2 diabetes to
determine if BMDCs play similar roles in both types of diabetes.
We next investigated the characteristics and origin of the abnormal
BMDCs, and if reversion to normoglycemia affects the abnormal
BMDCs formed during the hyperglycemic state.
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2.1. Establishment of diabetic mouse models and total bone marrow
transplantation (BMT)
C57BL/6Jmice (wild type, Japan CLEA, Osaka, Japan) and C57BL/6-
Tg (UBC-GFP) 30Scha/J mice (GFP-Tg mice, The Jackson Laboratory,
Bar Harbor, ME) were used. Hyperglycemia was induced by intrave-
nous injection of streptozotocin (STZ) (150 mg/kg) (Nacalai Tesque,
Kyoto, Japan) to create the type 1 diabetic model (STZ mice) or by
feedingahigh fatdiet (HFD) (Oriental bio service,Osaka, Japan) tocre-
ate the type 2 diabetic model (HFD mice). Mice injected with buffer
alone or fed normal chow were used as normoglycemic controls
(Ctrl), respectively, for type 1 and type 2. For BMT, we isolated bone
marrow cells from 8-week GFP-Tg mice. Wild type mice were irradi-
ated (9 Gy) and injectedwith 4  106 bonemarrowcells fromGFP-Tg
(GFP-BMTmice). Four weeks after BMT, hyperglycemia was induced
in GFP-BMT mice by STZ i.v. injection or by feeding a high fat diet.
Thesemicewere analyzed 9–12 weeks after STZ injection or the com-
mencement of high fat feeding. Blood glucose levels were measured
onceaweek inall experimentalmice. Theseanimalsweremaintained
under standard conditions with a 12:12-h light–dark cycle and pro-
vided with standard laboratory chow or high fat diet and water
ad libitum.
The Animal Care Committees of Shiga University of Medical Sci-
ence approved all experimental protocols performed in this study
(#2011-7-5HH).
2.2. Electrophysiological test
We performed sensory nerve conduction studies in mice using a
Medelec Sapphire EMG (Medelec, Woking, UK) under anesthesia
(pentobarbital sodium, 5 mg/kg i.p.) at 30 C to 32 C. We cut the
skin from the left dorsal surface of the thigh and exposed the sciatic
nerve. The sensory nerve action potential (SNAP) was recorded and
sensory nerve conduction velocity (SNCV) was calculated as previ-
ously described [1,3]. Since STZ mice and HFD mice were different
ages, we evaluated the results to compare the ratio against age
matched non-diabetic mice.
2.3. Immunohistochemical analysis
After blood removal and ﬁxative perfusion as previously de-
scribed [3], the DRG, tibiae and femora were used for immunohisto-
chemical analyses as described in Supplementary materials.
2.4. Flow cytometry and FACS sorting
After isolation of total bone marrow cells from femora, humeri
and tibiae in exsanguinated mice under anesthesia using sodium
pentobarbital (50 mg/kg i.p.), ﬂow cytometry and FACS sortingwere
performed as described in Supplementary materials.
2.5. Isolation of RNA, reverse transcription PCR and quantitative
RT-PCR
Isolation of RNA, RT-PCR and qRT-PCR were performed accord-
ing to the manufacturer’s protocol and analyzed as described in
Supplementary materials.
2.6. Bone marrow transplantation with KSL cells (KSL-BMT)
First, diabetes was induced in STZ diabetic mice by intravenous
administration of STZ into 7-week-old GFP-Tg mice. After
12 weeks, KSL cells were sorted from GFP-Tg mice with or withouthyperglycemia. Approximately 1  103 cells sorted as KSL cells
from hyperglycemic GFP-Tg mice were mixed with approximately
4  106 total bone marrow cells from wild-type mice, and were
transplanted into lethally-irradiated wild type-mice. Mice im-
planted with approximately 1  103 KSL cells from non-diabetic
GFP mice mixed with total bone marrow cells from wild-type mice
were used as controls. At 8 weeks after KSL-BMT, all mice were
used for analysis.
2.7. Statistical analyses
Data were evaluated using t-tests to analyze differences be-
tween 2 groups or ANOVA to analyze differences among 3 groups.
Data are expressed as means ± S.E. P < 0.05 was considered
signiﬁcant.
3. Results
3.1. Peripheral neuropathy occurs in hyperglycemic mice,
accompanied by the fusion of BMDCs with DRG neurons
We used two types of diabetic mouse models: a type 1 (induced
by STZ, referred to as STZ mice) and a type 2 (induced by high fat
diet, or HFD mice). Blood glucose levels in STZ and HFD mice were
474.8 ± 9.6 mg/dL (mean ± S.E., n = 13) and 271.2 ± 16.1 mg/dL
(n = 10), respectively, both levels were signiﬁcantly higher than
those in control chow mice (154.2 ± 10.3 mg/dL, n = 13)
(P < 0.01). Body weight was reduced in the STZ mice (21.67 ±
0.51 g, n = 13) compared to that of control mice (24.42 ± 0.63 g,
n = 13). (P < 0.01), and increased in HFD mice (39.72 ± 0.39 g,
n = 10), compared with those of control mice (P < 0.01).
We used nerve dysfunction as a measure of degree of nerve
damage caused by the peripheral neuropathy by measuring sen-
sory nerve conduction velocity (SNCV) in these mice. SNCV in
STZ mice was signiﬁcantly reduced by 30% compared with that
in control mice, which is consistent with our previous ﬁndings
(Fig. 1A, [1]). Similarly, SNCV in HFD mice was signiﬁcantly re-
duced by 20% compared with controls (Fig. 1A). Therefore, both
type 1 and type 2 mice exhibit signiﬁcant peripheral neuropathy.
We studied the STZ and HFDmodels after total bone marrow trans-
plantation (BMT) of BM from GFP-Tg mice to wild-type mice. In
agreement with our previous observations [1,2,9], we detected
immunoreactive GFP protein in a fraction of the DRG neurons that
were also MAP2 (neuronal marker)-positive in both types of dia-
betic mice (STZ (11.42 ± 1.39% in all MAP2 positive neurons) as
well as HFD (9.72 ± 1.57% in all MAP2 positive neurons), Fig. 1B),
whereas we did not detect GFP-positive staining in MAP2-positive
DRG neurons in non-diabetic control mice ([1], Fig. 1B, top panels).
The presences of GFP+ material in the DRG neurons of recipient
mice indicates that these are fusion cells between BMDCs and neu-
rons, as we documented extensively in prior publications [1,2,9].
Furthermore, GFP-expressing neurons also express insulin and
TNF-a (Fig. 1B, top panel). Of note, GFP-positive cells co-expressed
insulin and TNF-a were seen in both STZ and HFD diabetic mice
(Fig. 1B). These data indicate that DRG neurons display similar
aberrant phenomena in diabetic neuropathy that occurs in both
type 1 (STZ) and type 2 (HFD) diabetes mouse models.
3.2. Insulin- and TNF-a co-expressing cells in the bone marrow of
hyperglycemic mice
To determine the source of the abnormal BM-derived cells in
diabetes, we examined the BM of STZ and HFD diabetic mice by
immunohistochemistry and found the presence of immunoreactive
insulin and TNF-a proteins among BM cells in STZ (3.26 ± 0.09%) as
Fig. 1. Electrophysiological tests and immunoﬂuorescent overlap analysis of bone marrow-derived cells (BMDCs) and DRG neurons in control (Ctrl) and in STZ and high fat
diet (HFD) diabetic mice. (A) Relative ratio of sensory nerve conduction velocity in Ctrl (n = 6) compared to STZ (n = 10) and Ctrl (n = 5) compared to HFD (n = 6) mice. Data are
means ± S.E. ⁄⁄P < 0.01. (B) Immunoﬂuorescent co-staining of MAP2 (Red), Insulin (Red) or TNF-a (Red) with GFP (Green) and Nuclei (Blue) were carried out in DRG tissues.
Scale bars = 20 lm.
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Overlap immunoﬂuorescence analysis revealed that the two pro-
teins were co-localized in the BM cells of both STZ and HFD mice
(Fig. 2B).
Other laboratories have reported the induction of insulin
[10,11] and TNF-a [12] by hyperglycemia. Our data here and re-
ported previously [1,2,7,8] indicate that hyperglycemia induces
insulin and TNF-a expression in the BM of STZ and HFD mice.
We also documented previously the fusogenicity of the abnormal
BM-derived cells with DRG neurons, leading to diabetic neuropa-
thy [1,2,9]. We next sought to determine the BM subpopulations
which expressed the insulin ectopically. We isolated monocytes,
granulocytes, lineage negative cells and c-Kit+Sca-1+Lin (KSL) cells
from the BM. We ﬁrst screened the RNA isolated from these frac-
tions by traditional RT-PCR. We did a 40 cycle RT-PCR ampliﬁcation
to ensure that we detected even a low level expression of theinsulin gene. Under these conditions, in non-diabetic control mice,
we found detectable levels of insulin mRNA in all populations from
total bone marrow (TBM) to lineage negative fraction cells, but,
interestingly, we did not detect insulin transcripts in KSL cells
(Fig. 3A). On the other hand, we detected insulin mRNA in KSL cells
as well as all other fractions in STZ as well as HFD diabetic mice
(Fig. 3A). Quantitative real-time PCR analysis using isolated KSL
cells revealed that TNF-a expression in KSL cells in both STZ and
HFD mice was signiﬁcantly increased compared with that in con-
trol mice (P < 0.01, Fig. 3B); it was signiﬁcantly higher in KSL cells
isolated from HFD than those from STZ mice. To further quantify
these abnormal KSL cells, we performed ﬂow cytometry and found
a small but signiﬁcant number of cells which were both insulin-
and TNF-a positive in the population of KSL cells from both STZ
and HFD mice; such cells were not detectable in KSL cells from
control mice (Fig. 3C). Insulin-positive KSL cells constituted 0.7%
Fig. 2. Immunohistochemical analysis of insulin- and TNF-a-positive cells in the bone marrow. (A) Immunohistochemical staining of insulin- and TNF-a-positive cells in the
bone marrow. Arrows indicate positive staining for insulin or TNF-a. Scale bars = 10 lm. (B) Immunoﬂuorescent overlap staining of TNF-a (Red)/Insulin (Green)/Nuclei (Blue)
of bone marrow cells. Double-positive cells expressing both TNF-a and Insulin are shown surrounded with an interrupted line. Scale bars = 5 lm.
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the total KSL population in HFD mice (Fig. 3D). TNF-a cells repre-
sented 0.3% of the total population of KSL cells in STZ mice, while
they represented 0.2% in HFD mice.
Taken together, we conclude that hyperglycemia induces insu-
lin and TNF-a expression selectively in KSL cells, an early form of
hematopoietic stem cells.
3.3. HSCs exposed to high glucose mimic the pathogenesis of diabetic
neuropathy
Diabetes has been reported to cause a BM niche defect [13–15].
Hematopoietic stem cells (HSCs) and mesenchymal stem cells
(MSCs) are important constituents of the niche. Thus, there are
three possibilities for the abnormal progeny of KSL cells taking part
in the pathogenesis of neuropathy in diabetic mice: (1) Hypergly-
cemia directly affects HSCs, (2) Hyperglycemia indirectly affects
HSCs through the impairment of their microenvironment, or (3)
Both HSCs and MSCs are affected in hyperglycemia.
To answer these questions, we isolated KSL cells from untreated
control or STZ-treated diabetic GFP-Tg mice. We added these KSL
cells to total BM from normoglycemic mice, and transplanted them
into wild-type mice (Ctrl? KSL-BMT and STZ? KSL-BMT).
Immunohistochemical analysis revealed that the progeny of KSL
cells isolated fromSTZmice fusedwith DRG neurons in the non-dia-
betic recipient mice, as we observed in hyperglycemic mice
(4.73 ± 0.86% in all MAP2 positive neurons, compare Fig. 4 top panel
with Fig. 1B). Importantly, the fused neuronal cells in STZ?KSL-BMT produced both insulin and TNF-a (Fig. 4, middle and bot-
tom panels). Of note, there was no signiﬁcant difference in body
weight or in blood glucose level in STZ? KSL-BMT mice versus
Ctrl? KSL-BMT mice (data not shown).
Our results strongly suggest that hyperglycemia directly affects
HSCs rather than MSCs, leading to the fusion of their progeny with
DRG neurons and the production of insulin and TNF-a. Moreover,
once the BM phenotype is altered by hyperglycemia, the character-
istics of abnormal HSCs are preserved even if the hyperglycemic
environment is reverted to normoglycemic conditions.
4. Discussion
Previous studies in our laboratory showed that rodent (mouse
and rat)models of type1 (STZ)diabetesdevelopdiabeticneuropathy
with abnormal nerve function tests including impairment in SNCV.
In these animals, we detected abnormal insulin- and TNF-a co-
expressing BM-derived cells that fused with neurons in the DRG,
stimulating apoptosis and dysfunction as revealed by caspase3
expression, TUNEL and annexin V staining, abnormal Ca2+ transient
curve in DRG neurons, and contributed to the pathogenesis of dia-
beticneuropathy [1,2,9]. In this report,weshowed thatdiabeticneu-
ropathy characterized by abnormal SNCV also develop in type 2
(HFD) diabetic mice. Furthermore, the HFDmice also exhibit hyper-
glycemia-induced co-expression of insulin and TNF-a in the BM-
neuron fusion cells. Importantly, we have also uncovered that
hyperglycemia-induced insulin and TNF-a co-expression is
detected in a KSL population of BM cells in both type 1 and type 2
Fig. 3. The characteristics of BMDCs and their gene expression of insulin and TNF-a in Ctrl and in STZ and HFDmice. (A) Bands show the RT-PCR products of the insulin 1 gene
from the hematopoietic cell lineage fraction. Beta-actin was used as the internal control. TBM, total bone marrow cells; Mono, mononuclear cells; Gra, granulocytes; Lin (),
lineage negative cells; KSL, KSL cells. (B) Quantitative real-time PCR of TNF-amRNA expression in KSL cells. The value for the reference RNAs is arbitrarily assigned a value of
1.0 in Ctrl mice. Expression is shown as a standardized quotient divided by the value simultaneously obtained for beta-actin. Data are means ± S.E. ⁄P < 0.05, ⁄⁄P < 0.01; Ctrl:
n = 13, STZ: n = 13, HFD: n = 5. C: FACS analysis of KSL cells. The insulin-positive fraction of KSL cells (top panels). The arrow in the plot area indicates the population of
insulin-positive cells. The TNF-a positive fraction of KSL cells (bottom panels). The arrow in the plot area indicates TNF-a positive cells. (D) The percentages of insulin- or TNF-
a positive cells of KSL cells in Ctrl and STZ and HFDmice. For insulin analysis Ctrl (n = 8), STZ (n = 5) and HFD (n = 7). For TNF-a analysis Ctrl (n = 9), STZ (n = 9) and HFD (n = 3).
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pathogenesis of diabetic neuropathy.
Several groups have reported that incubation of BM cell in vitro
in high glucose induces the expression of insulin [10,11,16] and
TNF-a [12] mRNA. We previously demonstrated that hyperglyce-
mia induces the expression of insulin and TNF-a in BM cells
in vitro both at the mRNA and protein levels [1,7,9]. It is important
to note that in animals with diabetic neuropathy, the expression of
insulin in morphologically normal looking neurons (at the light
microscopy level) in the DRG has been shown in multiple experi-
ments to mark these cells as neuron-BM fusion cells (as docu-
mented by multiple BMT experiments [1,2,9], polyploidy [1,2],
and Y chromosome expression in these cells in male-to-female
BMT [1,2,9]). Poly (ADP-ribose) polymerase (PARP) activity had
been shown by multiple groups to be important in the pathogene-sis of diabetic complications including neuropathy [17,18]. We cor-
roborated this observation in STZ mice, and documented that (i)
PARP-knockout mice are resistant to diabetic neuropathy develop-
ment, (ii) BMT of PARP-knockout BM to wild type mice renders
them resistant to diabetic neuropathy, and (iii) BMT of PARP+ BM
from wild-type mice confers neuropathy susceptibility back to
PARP-knockout mice [2,9]. The protective effect of loss of PARP is
correlated with the down-regulation of hyperglycemia-induced
insulin and TNF-a expression as well as the propensity for the
BM cells to fuse with the neuronal cells [9]. Thus, hyperglycemia-
induced abnormalities in BM-derived cells are involved in the
pathogenesis of diabetic neuropathy.
Prior to the current study, it was unclear what if any particular
subpopulation of BM cells is selectively affected by hyperglycemia.
We have now shown that hyperglycemia induces the production of
Fig. 4. Immunoﬂuorescent co-staining of DRG neurons in the KSL-BMT study. Immunoﬂuorescent co-staining of MAP2 (Red), Insulin (Red) or TNF-a (Red) with GFP (KSL,
Green) and Nuclei (Blue) was performed in DRG neurons in non-diabetic mice after BMT with KSL cells from control (Ctrl? KSL-BMT) or STZ (STZ? KSL-BMT) mice. Scale
bars = 20 lm.
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kit+, Sca1+ and lineage cells in the BM and include early stage
HSCs [19]. Diabetes causes complications that involve multiple or-
gan systems such as nerve tissue, retina, kidney, gastrointestinal
tract and skin. The progeny of KSL cells are known to migrate to
multiple tissues from the BM, and aberrant HSCs could be the
source of cells that contribute to complications that involve a wide
range of tissues and organs in diabetes.
HSCs reside in bone marrow niches, which provide the microen-
vironment necessary for HSCs to maintain their stemness. The
microenvironment of the BM niche in chronic diabetes has been
shown to cause dysfunction of the hematopoietic stem cells [20].
The dysfunction of sympathetic nerve termini in the BM may be
associated with reduction in the number of BM stem cells [21].
Therefore, abnormal niche function could contribute to the emer-
gence of abnormal BM stem cells in hyperglycemia. In this study,
we added GFP-marked KSL cells isolated from hyperglycemic mice
to total BM cells from normoglycemic mice, and transplanted themixture into lethally-irradiated non-diabetic mice. It was most
informative that we detected GFP-positive GFP+ BM-derived cells
fused with neurons in the DRG of recipient mice. Importantly,
these GFP+ cells also expressed insulin and TNF-a, despite the pre-
vailing normoglycemic environment.
The GFP expression indicates that these BMDCs come from the
GFP+ KSL subpopulation isolated from hyperglycemic mouse do-
nors. Since insulin and TNF-a co-expression normally occurs in
the BM cells only in the presence of hyperglycemia, the expression
of these markers indicate that the KSL-derived progeny cells main-
tain their abnormal behavior by persistently express these
markers. The mechanism of the persistent expression of hypergly-
cemia-induced genes is unclear and will be the subject of future
investigations. A distinct possibility is that it may part of the
hyperglycemia-induced epigenetic modiﬁcations reported previ-
ously by others [22]. A form of ‘‘metabolic memory’’ was reported
in diabetic patients in whom improvements in glycemic control
does not seem to erase damage associated with prior exposure to
1086 M. Katagi et al. / FEBS Letters 588 (2014) 1080–1086severe hyperglycemia [23]. We speculate that the persistence of
abnormal marker expression in the KSL progeny cells, despite their
return to normoglycemia, may be a form of ‘‘metabolic memory at
the cell lineage level’’. Importantly, in addition to inappropriate
gene (insulin and TNF-a) expression, the progeny cells appear to
also maintain their fusogenicity, as demonstrated by their appear-
ance as BM-neuron cells in the DRG, a property that contributed to
the pathogenesis of diabetic neuropathy [1,2,9]. Our ﬁndings on
the passage of hyperglycemia-induced abnormal cell expression
and function from KSL cells to their progeny have important impli-
cations on the pathogenesis and treatment of diabetic
complications.
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